Published in Nat Cell Biol on February 16, 2015
Principles Governing A-to-I RNA Editing in the Breast Cancer Transcriptome. Cell Rep (2015) 1.21
A-to-I editing of coding and non-coding RNAs by ADARs. Nat Rev Mol Cell Biol (2015) 1.14
Gene amplification-associated overexpression of the RNA editing enzyme ADAR1 enhances human lung tumorigenesis. Oncogene (2015) 0.81
Selectively Constrained RNA Editing Regulation Crosstalks with piRNA Biogenesis in Primates. Mol Biol Evol (2015) 0.80
Emerging Role of MicroRNAs as Liquid Biopsy Biomarkers in Gastrointestinal Cancers. Clin Cancer Res (2017) 0.79
Long noncoding RNA HEIH promotes melanoma cell proliferation, migration and invasion via inhibition of miR-200b/a/429. Biosci Rep (2017) 0.76
Control of CREB expression in tumors: from molecular mechanisms and signal transduction pathways to therapeutic target. Oncotarget (2016) 0.76
Lineage-specific roles of the cytoplasmic polyadenylation factor CPEB4 in the regulation of melanoma drivers. Nat Commun (2016) 0.75
Functions of the RNA Editing Enzyme ADAR1 and Their Relevance to Human Diseases. Genes (Basel) (2016) 0.75
RNA Editing Dynamically Rewrites the Cancer Code. Trends Cancer (2015) 0.75
microRNA editing in seed region aligns with cellular changes in hypoxic conditions. Nucleic Acids Res (2016) 0.75
Aberrant overexpression of ADAR1 promotes gastric cancer progression by activating mTOR/p70S6K signaling. Oncotarget (2016) 0.75
miR-455-5p functions as a potential oncogene by targeting galectin-9 in colon cancer. Oncol Lett (2017) 0.75
Modifying microRNAs - another piece of the melanoma puzzle. Pigment Cell Melanoma Res (2015) 0.75
CPEB1 restrains proliferation of Glioblastoma cells through the regulation of p27(Kip1) mRNA translation. Sci Rep (2016) 0.75
Accurate detection for a wide range of mutation and editing sites of microRNAs from small RNA high-throughput sequencing profiles. Nucleic Acids Res (2016) 0.75
RNA Editing, ADAR1, and the Innate Immune Response. Genes (Basel) (2017) 0.75
Characteristic miRNA expression signature and random forest survival analysis identify potential cancer-driving miRNAs in a broad range of head and neck squamous cell carcinoma subtypes. Rep Pract Oncol Radiother (2017) 0.75
Systematic characterization of A-to-I RNA editing hotspots in microRNAs across human cancers. Genome Res (2017) 0.75
Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics (2009) 190.94
Cancer statistics, 2014. CA Cancer J Clin (2014) 72.81
RNA editing by adenosine deaminases that act on RNA. Annu Rev Biochem (2001) 9.66
Melanoma. N Engl J Med (2006) 8.80
Systematic identification of abundant A-to-I editing sites in the human transcriptome. Nat Biotechnol (2004) 7.61
Modulation of microRNA processing and expression through RNA editing by ADAR deaminases. Nat Struct Mol Biol (2005) 7.49
Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev (2010) 4.75
Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res (2005) 4.24
RNA editing of the microRNA-151 precursor blocks cleavage by the Dicer-TRBP complex. EMBO Rep (2007) 3.40
Unbalanced alternative splicing and its significance in cancer. Bioessays (2006) 3.17
A neuronal isoform of CPEB regulates local protein synthesis and stabilizes synapse-specific long-term facilitation in aplysia. Cell (2003) 3.15
The many roles of an RNA editor. Nat Rev Genet (2001) 2.55
A-to-I RNA editing: recent news and residual mysteries. J Biol Chem (2002) 2.20
Microphthalmia gene product as a signal transducer in cAMP-induced differentiation of melanocytes. J Cell Biol (1998) 2.20
Evolutionarily conserved human targets of adenosine to inosine RNA editing. Nucleic Acids Res (2005) 1.96
Editing independent effects of ADARs on the miRNA/siRNA pathways. EMBO J (2009) 1.76
Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. Cancer Res (2008) 1.65
ADAR1 forms a complex with Dicer to promote microRNA processing and RNA-induced gene silencing. Cell (2013) 1.57
RNA editing and alternative splicing: the importance of co-transcriptional coordination. EMBO Rep (2006) 1.48
Platelet-activating factor mediates MMP-2 expression and activation via phosphorylation of cAMP-response element-binding protein and contributes to melanoma metastasis. J Biol Chem (2005) 1.38
CREB and its associated proteins act as survival factors for human melanoma cells. J Biol Chem (1998) 1.37
Systematic identification of edited microRNAs in the human brain. Genome Res (2012) 1.35
A-to-I RNA editing and cancer: from pathology to basic science. RNA Biol (2008) 1.32
Origins and evolution of ADAR-mediated RNA editing. IUBMB Life (2009) 1.19
Silencing cAMP-response element-binding protein (CREB) identifies CYR61 as a tumor suppressor gene in melanoma. J Biol Chem (2009) 1.18
MicroRNA-mediated loss of ADAR1 in metastatic melanoma promotes tumor growth. J Clin Invest (2013) 1.11
Transcriptional control of the melanoma malignant phenotype. Cancer Biol Ther (2008) 1.08
Dominant-negative CREB inhibits tumor growth and metastasis of human melanoma cells. Oncogene (1997) 1.08
Human BLCAP transcript: new editing events in normal and cancerous tissues. Int J Cancer (2010) 1.04
CPEB1, a novel gene silenced in gastric cancer: a Drosophila approach. Gut (2011) 1.02
Editing of neurotransmitter receptor and ion channel RNAs in the nervous system. Curr Top Microbiol Immunol (2012) 1.01
Over-expression of Aurora-A targets cytoplasmic polyadenylation element binding protein and promotes mRNA polyadenylation of Cdk1 and cyclin B1. Genes Cells (2005) 0.96
Modulation of microRNA expression and function by ADARs. Curr Top Microbiol Immunol (2012) 0.94
Adenosine-to-inosine RNA editing. Wiley Interdiscip Rev Syst Biol Med (2010) 0.92
Driving transcriptional regulators in melanoma metastasis. Cancer Metastasis Rev (2012) 0.92
CREB inhibits AP-2alpha expression to regulate the malignant phenotype of melanoma. PLoS One (2010) 0.92
A mammalian reporter system for fast and quantitative detection of intracellular A-to-I RNA editing levels. Anal Biochem (2010) 0.91
Cytoplasmic polyadenylation element binding protein is a conserved target of tumor suppressor HRPT2/CDC73. Cell Death Differ (2010) 0.82